Clinical Oncological Tolerance of Testosterone Replacement Therapy Over Two Years Among Patients With High-Risk or Very High-Risk Prostate Cancer Undergoing Radiotherapy
TRT for two years might be tolerated for cancer control among patients with high-risk prostate cancer who had undergone radiotherapy. Since this was a retrospective study without a control group, further prospective studies, including a large number of subjects and a control group, are required to reach a more definite conclusion.
Authors
- Tetsuya Kawahara (ORCID: https://orcid.org/0000-0002-1268-4871)
- Takahiro Nohara (ORCID: https://orcid.org/0000-0001-9792-2068)
- Atsushi Mizokami (ORCID: https://orcid.org/0000-0002-5643-2182)
- Yuki Kato (ORCID: https://orcid.org/0000-0002-1833-5381)
- Kazuyoshi Shigehara (ORCID: https://orcid.org/0000-0002-2118-9135)
- Rei Shinzawa (ORCID: https://orcid.org/0009-0002-1781-2817)
- Kouji Izumi
- Renato Naito
- Hiroshi Yaegshi
Institutions
- Kanazawa University (JP)
- Fukui-ken Saiseikai Hospital (JP)
Publication Details
- Journal
- Cureus
- Published
- 2025-09-20
- DOI
- https://doi.org/10.7759/cureus.92806
- Primary Topic
- Hormonal and reproductive studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00